Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-05
1997-12-16
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514250, 514411, 514415, 514657, A61K 31445, A61K 31405, A61K 3140, A61K 3113
Patent
active
056985711
ABSTRACT:
The present invention provides a method for the treatment of migraine with compounds or compositions that are selective agonists of 5-HT.sub.1F receptors relative to other serotonin receptors that produce unwanted effects like vasoconstriction. The neurogenic meningeal extravasation that leads to the pain of migraine is inhibited.
REFERENCES:
Lee et al., American Journal of Physiology, 266 (3 Pt. 2) H1000-6, 1994.
Moskowitz, M.A., TiPS, 13 (8), 307-311 (1972).
Moskowitz, M.A., and Macfarlane, Robert, Cerebrovascular and Brain Metabolism Reciews, 5, 159-177 (1993).
Fozard, J.R., "Migraine: A Spectrum of Ideas", Sandler, M., and Collins, G.M. (eds.), Oxford University Press: New York (1990).
Moskowitz, M.A., Neurology, 43 (Suppl 3), 16-20 (1993).
Silberstein, S.D., Headache, 34, 408-417 (1994).
Adham, et al., Prac. Natl. Acad. Sci., 90, 408-412 (1993).
Audia James E.
Branchek Theresa
Cohen Marlene L.
Johnson Kirk W.
Phebus Lee A.
Boone David E.
Eli Lilly and Company
Spivack Phyllis G.
Titus Robert D.
LandOfFree
5-HT.sub.1F mediated inhibition of neurogenic meningeal extravas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-HT.sub.1F mediated inhibition of neurogenic meningeal extravas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT.sub.1F mediated inhibition of neurogenic meningeal extravas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-206571